Clinical Trial

Pharmacokinetics Study of Larotinib in Subjects With Impaired Hepatic Function

Not Yet Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
To evaluate the pharmacokinetics and safety of Larotinib in subjects with mild and moderate hepatic function impairment and healthy subjects in a single-center, non-randomized, open, single-dose administration
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2021-09-08; most recent amendment 2025-05-16.
Trial Details
NCT Number NCT05048368
Lead Sponsor Sunshine Lake Pharma Co., Ltd.
Conditions Esophageal Cancer, Advanced Solid Tumor
Enrollment 32 participants
Start Date 2026-10-30
Primary Completion 2026-12-30 (estimated)
Study Completion 2026-12-30 (estimated)
Updated on ClinicalTrials.gov 2025-05-18